A New Line Of Sight
Into Targeted Cancer Therapies

Our team is comprised of leading industry experts with deep radiotherapy development experience

Frances L. Johnson, MD
Co-Founder, Chief Executive Officer

Frances L. Johnson, MD is a physician scientist and entrepreneur with experience leading multi-disciplinary teams in academic, government and private enterprise settings. Dr. Johnson received a BS in Cell and Molecular Biology and a Doctorate in Medicine from the University of Washington followed by Internal Medicine residency at the University of California San Francisco and Cardiovascular Medicine fellowship at Stanford University. Her experience includes co-founding a biomedical startup (XDx; now CareDx, NASDAQ:CDNA) as a co-inventor of their molecular diagnostic technology while on Stanford’s faculty. Dr. Johnson remained in academics during the growth phase of CareDx and led heart transplant teams at three academic medical centers before co-founding Viewpoint Molecular Targeting with Dr. Schultz and Mr. Coleman. As CEO at Viewpoint, Dr. Johnson has successfully secured multiple competitive Phase I and Phase II National Institutes of Health/National Cancer Institute funded Small Business Innovation Research Grants and Contract Projects ($10M). Dr. Johnson has successfully developed a team that has secured the first of two IND approvals expected in 2021 to begin the clinical trials of Viewpoint radiopharmaceuticals.


Michael K. Schultz, PhD
Co-Founder, Chief Science Officer

Michael K. Schultz, PhD is the principal inventor of Viewpoint’s radiopharmaceuticals and directs ongoing development programs. Dr. Schultz is concurrently an Associate Professor of Radiology and Free Radical and Radiation Biology at the University of Iowa. Dr. Schultz has maintained continuous research funding for his laboratory for over a decade from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and has published over 75 peer-reviewed journal articles, book chapters, and invited publications. Dr. Schultz (as Co-Principal Investigator) was awarded a competitive NIH Research Project Grant (R01) to perform the non-clinical research and development needed to advance Viewpoint’s alpha-particle therapy for neuroendocrine tumors to a Phase 1 clinical imaging and therapy trial to be conducted at the University of Iowa. Dr. Schultz is Principal Investigator or Co-Investigator (with CEO and CMO Frances Johnson, MD of Viewpoint) on over $10M of NCI funded Small Business Innovation Research grant projects. In addition to his role on the current R01 ($3.5M), Dr. Schultz is a Project Leader for the University of Iowa NIH sponsored Specialized Project of Research Excellence in Neuroendocrine Tumors (a $10M, 5-year grant) and has been the primary architect, Principal Investigator, or Co-Investigator on over $20M in total of grants from the NIH, Nuclear Regulatory Commission, Department of Energy, Department of Homeland Security, and industry funded research projects. Dr. Schultz has five years of experience in product management in radiation detectors, electronics, and software (PerkinElmer/Ametec) and 17 years of experience in radiopharmaceutical CMC/IND approvals, including as a consultant to Algeta ASA (acquired by Bayer) on the CMC for the first alpha-particle targeted therapy approved in the United States.

Amos Hedt
Chief Business Strategy Officer

Mr. Hedt is an experienced research professional with over 20 years in the biotechnology and pharmaceutical industries and a comprehensive understanding of all stages of drug research, development, and product innovation. He has extensive experience and knowledge managing clinical projects with a concentration in early-stage drug development specializing in theranostics, radiopharmaceuticals, mAbs, and vaccines. 

Mr. Hedt joins the Viewpoint team having most recently served as the Founder and Principal Consultant at Cedalion, a strategic consulting and contract research practice specializing in the biotechnology, pharmaceutical, and diagnostic industries, working to provide strategic development plans, analysis of database and literature, and insight into the competitive landscape for an optimized approach to novel developments. Prior to that, he served as Head of Clinical Development and Strategy for Clarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company developing theranostics for the diagnosis and therapy of cancer, where he played a vital role in the design and implementation of clinical trial programs that drove research and development strategies and advancements. Additionally, Mr. Hedt served as Senior Director, Clinical Operations for Patrys Ltd., a clinical-stage biotechnology company focused on the development of an entirely new type of product for the treatment of cancer – natural human antibodies. He also held a variety of roles at CSL Ltd., an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent severe human medical conditions. 

Mr. Hedt received his Bachelor of Arts in Psychophysiology and Psychology from the Swinburne University of Technology and completed his Graduate and Postgraduate training in the History and Philosophy of Science at the University of Melbourne.